CaliPharms, Inc. (OTCPink: KGET), a Development Stage Company operating in the California Medicinal Cannabis Industry, publicly trading under the OTC Markets symbol "KGET" has entered discussions with a Beverage Master Distributor.
Management has concluded extensive research on the CBD beverage market and determined it is an excellent market for CaliPharms to enter at this time in the USA. CaliPharms has entered discussions to acquire the master distributorship with the intention of developing its own CBD Beverage line and using the distribution channels to place future products.
Cannabidiol (CBD) is a natural compound found in cannabis and is known for its medicinal benefits. It is the compound of cannabis minus the THC or illusionary compound. CBD is now legal in most states of the USA, Canada and 22 countries in Europe with increasing pressures on Governments to completely legalize its use;
In the US CBD market is estimated to grow to $2.1B by 2020* (Investing News, 2017), whilst the International market for cannabis is projected to hit $31.4 billion by 2021 (Zhang, M 2017)
The benefits of CBD are being recognized by more international
governments and more countries are continuing to legalize its use. Greece
is one of 22 new countries to lift restrictions on cannabis use.
Recent articles on the growth and value of CBD companies are provided for reference;
CaliPharms President Bo Linton stated, “We have entered discussions with a beverage master distributor and believe we are close to making a deal that will include distribution of existing CBD Beverages which we expect to evolve into a proprietary “CaliPharms” brand of CBD beverages.” Linton continued, “This is an exciting time at CaliPharms as the climate appears to be just right for a new CBD beverage product launch.”
About CaliPharms, Inc.
CaliPharms Inc., trading under the symbol (KGET) which trades under its former name Kleangas Energy Technologies, Inc. is a development stage business. The Company currently is focused on an acquisition within the Last Mile Delivery sector.
Safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as CaliPharms or KGET or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Investment into a microcap company is a high risk investment and it should only be considered if you are able to afford a total loss of the investment. Laws and Regulations of Marijuana are currently in direct contradiction between California and Federal Law and these factors should be a part of your consideration when making an investment into KGET.
Company Contact:
CaliPharms, Inc. (KGET)
Telephone 1-949-800-6645
Email: info@CaliPharmsInc.com